Rinie Bajracharya

Rinie Bajracharya
The University of Queensland | UQ · Institute for Molecular Bioscience

PhD

About

5
Publications
322
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
15
Citations
Education
January 2018 - October 2021
The University of Queensland
Field of study
  • Neuroscience
February 2017 - November 2017
The University of Queensland
Field of study
  • Neuroscience
March 2014 - November 2016
The University of Queensland
Field of study
  • Biomedical Science

Publications

Publications (5)
Article
Tau-specific immunotherapy is an attractive strategy for the treatment of Alzheimer's disease and other tauopathies. However, effectively targeting tau in the brain remains a considerable challenge due to the restrictive nature of the blood-brain barrier (BBB), which excludes an estimated >99% of peripherally administered antibodies. However, their...
Article
Full-text available
For the treatment of neurological diseases, achieving sufficient exposure to the brain parenchyma is a critical determinant of drug efficacy. The blood–brain barrier (BBB) functions to tightly control the passage of substances between the bloodstream and the central nervous system, and as such poses a major obstacle that must be overcome for therap...
Preprint
Full-text available
Tau-specific immunotherapy is an attractive therapeutic strategy for the treatment of Alzheimer's disease and other tauopathies. However, targeting tau effectively remains a considerable challenge due to the restrictive nature of the blood-brain barrier (BBB), which excludes 99.9% of peripherally administered antibodies. We have previously shown th...
Article
Full-text available
One of the main pathological hallmarks of Alzheimer’s disease (AD) is the intraneuronal accumulation of hyperphosphorylated tau. Passive immunotherapy is a promising strategy for the treatment of AD and there are currently a number of tau-specific monoclonal antibodies in clinical trials. A proposed mechanism of action is to engage and clear extrac...

Network

Cited By